ReCode Therapeutics is a Biotech company based in Menlo Park, CA. It has raised $570M in total funding. Latest round: Series B.
ReCode Therapeutics is a Biotech company based in Menlo Park, CA. ReCode Therapeutics has raised $570M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series B announced in September 2025. The round record for ReCode Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include OrbiMed, Colt Ventures, InterWest, MPM Capital, Pfizer Venture Investments, Vida Ventures and 9 others. 15 distinct backers are named across the disclosed rounds.
Every ReCode Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Menlo Park at a similar stage.
The investor deck ReCode Therapeutics used to raise — 2023, Series B, 13-slide deck is broken down slide by slide, including the slides it leads with and the questions it leaves open.
Company funding database · Investor directory · Founder database · Mega-rounds 2026